Gilgamesh Pharmaceuticals
Jeff Moehlenkamp currently serves as the VP and Head of Toxicology at Gilgamesh Pharmaceuticals since May 2025. Prior to this role, Jeff held the position of Executive Director of Toxicology at Bristol Myers Squibb from March 2024 to March 2025, and at Karuna Therapeutics from June 2021 to March 2024. Jeff's earlier experience includes Senior Director of Toxicology at Aclairo Pharmaceutical Development Group and various roles at Bristol-Myers Squibb, including Associate Director of Toxicology Operations. Educational qualifications consist of a PhD in Pharmacology/Toxicology from the University of Kansas Medical Center and a B.S. in Biology from Butler University.
This person is not in any teams
This person is not in any offices